Compare Eli Lilly And Co (LLY) vs TeraWulf Inc (WULF) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.

LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.

WULF trades at $13.65, down 5.21% today, amid a bearish technical signal and volatile AI infrastructure sector sentiment. The company reported a net loss of $661.42 million in 2025 with a negative net income margin of -392.64%, while revenue was $168.46 million. Recent news highlights its pivot to AI data centers, with stock movements influenced by sector-wide trends and analyst coverage.

Outlook remains speculative with high valuation ratios (P/S 35.73, P/B 46.24) and persistent losses posing risks, but 100% analyst buy ratings and a $34.92 consensus price target suggest long-term growth potential from AI hosting contracts. Key risks include execution challenges and competitive pressures in the evolving AI infrastructure space.